RPS6KA3 and melanoma: Corresponding to the decreased survival and/or the induction of cell cycle arrest upon RSK inhibition, we detected a strong suppression of spheroid growth throughout the mutational melanoma subgroups by PMD-026, which was confirmed by the second RSK inhibitor BI-D1870 (Fig. 3A, B; Suppl.